ADC Therapeutics S.A.

NYSE: ADCT · Real-Time Price · USD
3.13
-0.06 (-1.88%)
At close: Aug 15, 2025, 3:59 PM
3.13
-0.04%
After-hours: Aug 15, 2025, 06:42 PM EDT

ADC Therapeutics S.A. Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
17.4M 16.91M 18.46M 17.41M 18.05M 16.79M 14.49M 19.28M 18.99M 69.8M 76.32M 17.29M 46.5M 17.01M 13.15M 3.76M n/a
Cost of Revenue
2.06M 1.37M 851K 2.06M 3.35M 1.22M 366K 1.32M 590K 489K 1.29M 2.27M 529K 770K 502K 121K 578K
Gross Profit
15.34M 15.54M 17.61M 15.36M 14.7M 15.57M 14.13M 17.96M 18.4M 69.31M 75.03M 15.03M 45.97M 16.24M 12.64M 3.64M -578K
Operating Income
-28.46M -32.44M -35.56M -29.04M -33.61M -39.98M -37.4M -39.79M -51.57M -10.74M 6.87M -69.41M -40.36M -62.78M -57.79M -70.48M -70.67M
Interest Income
2.05M 2.63M 3.44M 3.25M 2.95M 3.29M 3.14M 2.37M 2.3M 1.63M 273K 16K 18.31M 20K 16K 15K 15K
Pretax Income
-38.44M -31.05M -43.62M -36.03M -46M -39.87M -47.89M -53.73M -59.69M -20.19M -51.32M -65.32M -17.83M -56.35M -71.4M -72.33M -51.42M
Net Income
-38.6M -30.73M -43.97M -36.54M -46.61M -85.03M -47.81M -47.12M -59.43M -24.16M -50.61M -64.37M -16.66M -34.38M -71.55M -72.57M -51.53M
Selling & General & Admin
-598K 20.87M 20.68M 20.94M 23.42M 25.22M 23.09M 26.46M 30.49M 31.31M 36.46M 35.9M 37.38M 36.53M 33.63M 34.59M 31.49M
Research & Development
28.93M 27.1M 32.5M 24.3M 25.73M 30.33M 28.44M 31.94M 39.48M 48.73M 41.68M 48.54M 48.95M 42.49M 36.8M 39.53M 39.17M
Other Expenses
n/a n/a n/a 2.23M 263K n/a n/a 296K n/a n/a n/a 114K 8K n/a n/a n/a n/a
Operating Expenses
28.33M 47.98M 53.18M 44.4M 48.31M 55.55M 51.53M 57.75M 69.97M 80.05M 78.14M 84.44M 86.33M 79.02M 70.44M 74.12M 70.67M
Interest Expense
12.23M 11.92M 13.12M 12.68M 12.5M 7.67M 12.94M 10.31M 10.42M 9.8M 11.36M 8.8M 9.22M 9.52M 4.26M 2.56M 2M
Selling & Marketing Expenses
-10.55M 5.72M 5.06M 4.85M 5.81M 13.93M 8.04M 8.33M 15.35M 16.18M 8.24M 17.66M 18.37M 18.6M 17.05M 15.22M 13.91M
Cost & Expenses
30.39M 49.35M 54.03M 46.45M 51.67M 56.77M 51.9M 59.07M 70.56M 80.54M 79.44M 86.7M 86.86M 79.79M 70.94M 74.24M 70.67M
Income Tax Expense
-165K -321K 90K -86K -84K 43.17M -86K -6.61M -262K 3.97M -711K -947K -1.17M -21.97M 145K 240K 107K
Shares Outstanding (Basic)
107.2M 105.4M 104.82M 95.69M 82.55M 82.29M 82.26M 81.47M 80.81M 80.64M 78.37M 76.91M 76.82M 76.4M 76.74M 76.73M 76.72M
Shares Outstanding (Diluted)
107.2M 105.4M 104.82M 95.69M 82.55M 82.29M 82.26M 81.47M 80.81M 80.64M 78.37M 76.91M 76.82M 76.4M 76.74M 76.73M 76.72M
EPS (Basic)
-0.36 -0.29 -0.42 -0.38 -0.56 -1.03 -0.58 -0.58 -0.74 -0.3 -0.65 -0.84 -0.22 -0.45 -0.93 -0.95 -0.67
EPS (Diluted)
-0.36 -0.29 -0.42 -0.38 -0.56 -1.03 -0.58 -0.58 -0.74 -0.3 -0.65 -0.84 -0.22 -0.45 -0.93 -0.95 -0.67
EBITDA
-28.46M -18.57M -29.7M -22.52M -32.66M -26.96M -32.99M -37.12M -47.35M -8.3M -37.38M -54.13M -5.52M -43.31M -64.27M -69.14M -48.31M
EBIT
n/a -19.13M -30.5M -23.35M -33.51M -26.96M -33.79M -42.34M -48.05M -12.64M -39.96M -56.52M -6.11M -46.83M -64.93M -69.77M -48.89M
Depreciation & Amortization
n/a 793K 802K 838K 843K 1.01M 793K 769K 694K 802K 572K 586K 594K 759K 658K 635K 578K